Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VRK3 shRNA
- Development stage
- Preclinical
- Lead developer
- Academia Sinica
- Modality
- Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Parenteral
01
Overview
VRK3 shRNA is a short hairpin RNA (shRNA) designed to knock down the expression of vaccinia-related kinase 3 (VRK3). In preclinical research, knocking down VRK3 in breast cancer cells has been shown to sensitize them to paclitaxel, reducing the IC50 of paclitaxel by half. This suggests a potential role for VRK3 inhibition in overcoming paclitaxel resistance in breast cancer.
- Other names
- VRK3 short hairpin RNAVRK-3 short hairpin RNAVRK 3 short hairpin RNA
02
Targets
Pseudokinase (Pseudokinase family)
Beyond the preview
Go deeper on VRK3 shRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VRK3 shRNA.